Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 738

1.

New age of neuroproteomics in Alzheimer's disease research.

Kovacech B, Zilka N, Novak M.

Cell Mol Neurobiol. 2009 Sep;29(6-7):799-805. doi: 10.1007/s10571-009-9358-6. Epub 2009 Feb 19. Review.

PMID:
19225878
2.

Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.

Padmanabhan J, Levy M, Dickson DW, Potter H.

Brain. 2006 Nov;129(Pt 11):3020-34. Epub 2006 Sep 20.

PMID:
16987932
3.
4.

Transition of tau protein from disordered to misordered in Alzheimer's disease.

Kovacech B, Skrabana R, Novak M.

Neurodegener Dis. 2010;7(1-3):24-7. doi: 10.1159/000283478. Epub 2010 Feb 13.

PMID:
20160453
5.

Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.

Pei JJ, Sjögren M, Winblad B.

Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b. Review.

PMID:
18852562
6.

Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.

Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M.

FEBS Lett. 2006 Jun 26;580(15):3582-8. Epub 2006 May 22.

7.

Truncation of tau protein and its pathological significance in Alzheimer's disease.

García-Sierra F, Mondragón-Rodríguez S, Basurto-Islas G.

J Alzheimers Dis. 2008 Aug;14(4):401-9. Review.

PMID:
18688090
8.

Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.

Zhang Q, Zhang X, Sun A.

Acta Neuropathol. 2009 Jun;117(6):687-97. doi: 10.1007/s00401-009-0491-6. Epub 2009 Feb 4.

PMID:
19190923
10.

A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.

Amadoro G, Corsetti V, Stringaro A, Colone M, D'Aguanno S, Meli G, Ciotti M, Sancesario G, Cattaneo A, Bussani R, Mercanti D, Calissano P.

J Alzheimers Dis. 2010;21(2):445-70. doi: 10.3233/JAD-2010-100120.

PMID:
20571215
11.

Regulation of tau phosphorylation in Alzheimer's disease.

Lee VM.

Ann N Y Acad Sci. 1996 Jan 17;777:107-13. Review.

PMID:
8624072
12.

Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.

Keck S, Nitsch R, Grune T, Ullrich O.

J Neurochem. 2003 Apr;85(1):115-22.

13.

Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.

Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2005 Jan;109(1):25-31. Epub 2005 Jan 11. Review.

PMID:
15645264
15.

Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Filipcik P, Cente M, Krajciova G, Vanicky I, Novak M.

Cell Mol Neurobiol. 2009 Sep;29(6-7):895-900. doi: 10.1007/s10571-009-9372-8. Epub 2009 Mar 5.

PMID:
19263214
16.

Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.

David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J.

Proteomics. 2006 Dec;6(24):6566-77.

PMID:
17111439
17.

Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.

Cente M, Filipcik P, Pevalova M, Novak M.

Eur J Neurosci. 2006 Aug;24(4):1085-90.

PMID:
16930434
18.

Tau therapeutics for Alzheimer's disease: the promise and the challenges.

Gold M.

J Mol Neurosci. 2002 Dec;19(3):331-4. Review.

PMID:
12540060
19.

Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.

Iqbal K, Grundke-Iqbal I.

Curr Drug Targets. 2004 Aug;5(6):495-502. Review.

PMID:
15270196
20.

Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.

Obulesu M, Venu R, Somashekhar R.

Neurochem Res. 2011 Aug;36(8):1329-35. doi: 10.1007/s11064-011-0475-5. Epub 2011 Apr 21. Review.

PMID:
21509508

Supplemental Content

Support Center